Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic.

Paulo Eduardo StangaFrancisco Javier Valentín-BravoSebastian Eduardo Francis StangaUrsula Inge ReinsteinSalvador Pastor-IdoateSusan M Downes

Published in: Eye (London, England) (2023)

Real-world outcomes showed improvement in BCVA and anatomic parameters at an early timepoint, demonstrating the efficacy and durability of faricimab in nAMD patients. Larger numbers of patients and longer follow-up are needed to determine whether the loading dose is required in all, what percentage of patients experience an improvement, and whether improvement it is maintained.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
primary care
metabolic syndrome
endothelial cells
optical coherence tomography
insulin resistance
weight loss
vascular endothelial growth factor